CVSA

Covista Inc. CVSA reported exceptional fourth-quarter fiscal 2026 (ended June 30, 2026) results with adjusted earnings and revenues topping the Zacks Consensus Estimate and growing year over year.Growth was broad-based across all three segments, while operating efficiencies supported profitability. Total student enrollment increased 8.4% to 99,472, marking the 12th straight quarter of year-over-year growth, with Walden reaching its highest enrollment in university history.CVSA stock inched up 0.8% during yesterday’s after-hours trading session. Adjusted earnings were $2.09 per share, up 25.9% year over year and 10% above the Zacks Consensus Estimate of $1.90.Revenues increased 9.7% to $501.4 million year over year and beat the consensus mark of $485 million by 3.4%. Covista Inc. price-consensus-eps-surprise-chart | Covista Inc. Quote Adjusted EBITDA rose 15.2% year over year to $126.9 million, while adjusted EBITDA margin expanded 120 basis points to 25.3%. Management attributed the improvement to revenue growth and operational efficiencies, partly offset by elevated investment in strategic growth initiatives.Adjusted operating income increased 15.3% to $100.9 million, and adjusted operating margin improved to 20.1% from 19.1%. Adjusted net income rose to $72.8 million from $62.4 million. Chamberlain revenues rose 3.2% to $190.2 million. Segment adjusted EBITDA increased 3.8% year over year to $46.8 million. Chamberlain students increased 1.6% to 39,501, the segment's second straight quarter of positive total enrollment growth. Its pre-licensure BSN program posted a 16th straight quarter of year-over-year enrollment growth, while management cited targeted operational enhancements as supporting new enrollment and future trends.Walden University’s revenues increased 15.7% to $210.8 million as healthcare and non-healthcare programs supported growth. Adjusted EBITDA of the segment grew 32.3% to $69.7 million compared with the year-ago quarter. Walden University enrollment rose 14% to 54,851, its 12th straight quarter of year-over-year growth and highest growth rate of fiscal 2026.Medical and Veterinary revenues advanced 10.7% to $100.3 million. Segment adjusted EBITDA increased year over year by 12.3% to $22.5 million. Enrollment increased 7.3% to 5,120, with growth led by Medical and new-enrollment acceleration at both Medical and Veterinary. During the full fiscal year, revenues of $1.95 billion grew 9.3% year over year.Adjusted EBITDA was up 13.5% to $521.7 million from $459.7 million reported in fiscal 2025. Adjusted EBITDA margin expanded year over year to 26.7% from 25.7%.Adjusted EPS was $8.25, up year over year by 23.7% from $6.67 reported in fiscal 2025. Chamberlain and Advocate Health launched a nursing collaboration combining scholarships, clinical immersion, employment pathways and loan repayment support. Chamberlain also plans new campuses in Cincinnati and Salt Lake City, with classes expected to begin in the first half of fiscal 2027.Walden programs launched heading into the 2026 academic year enrolled more than 1,700 students, and four additional programs began enrolling after quarter-end. Covista also added nine AI professional certificates with Google Cloud during Q4; more than 9,000 learners have enrolled across its 12 available AI credentials. These initiatives align with Purpose at Scale, which emphasizes operational excellence, platform extension, employer integration and technology. Fiscal 2026 free cash flow rose 38.7% to $393.1 million. Net cash provided by operating activities from continuing operations increased to $470.8 million from $333.7 million, while capital expenditures rose to $77.7 million from $50.3 million. Covista ended June with $406.3 million in cash and cash equivalents and net leverage of 0.5x.The company repurchased $238 million of shares in fiscal 2026, leaving $661.8 million under its $750 million authorization. It also repaid $50 million of Term Loan B debt and refinanced outstanding debt while increasing revolving credit capacity. For fiscal 2027, Covista expects revenues of $2.05-$2.09 billion, representing roughly 5-7% growth. Adjusted earnings are projected at $8.90-$9.15 per share, implying about 8-11% growth year over year.Management expects revenue growth to be stronger in the second half than in the first half due to Walden shifting one academic week from the second quarter into the third quarter. It also targets 0-50 basis points of adjusted EBITDA margin expansion, with the capital expenditure run rate slightly above annualized fourth-quarter fiscal 2026 spending and continued strong cash flow. Covista currently carries a Zacks Rank #3 (Hold). TAL Education Group TAL presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The company has a trailing four-quarter earnings surprise of 210%, on average. The Zacks Consensus Estimate for TAL Education’s fiscal 2027 sales indicates growth of 22.3% while EPS reflects a decline of 14.1% from the year-ago period’s levels.American Public Education, Inc. APEI currently carries a Zacks Rank #2 (Buy). The company has a trailing four-quarter earnings surprise of 157.7%, on average. The Zacks Consensus Estimate for American Public’s 2026 sales and EPS indicates growth of 90.4% and 6.5%, respectively, from the year-ago period’s levels. The combination of a positive Earnings ESP and a Zacks Rank of 1, 2 or 3 increases the odds of an earnings beat.Strategic Education, Inc. STRA currently has an Earnings ESP of +2.38% and a Zacks Rank of 3.Strategic Education’s earnings beat estimates in two of the last four quarters and missed on the remaining two occasions, the average surprise being 9%. The company’s earnings for the third quarter of 2026 are expected to grow 16.6% year over year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Covista Inc. (CVSA) : Free Stock Analysis Report American Public Education, Inc. (APEI) : Free Stock Analysis Report Strategic Education Inc. (STRA) : Free Stock Analysis Report TAL Education Group (TAL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

This article first appeared on GuruFocus. Revenue: Fourth-quarter revenue increased 9.7% to $501.4 million; full-year revenue was $1.954 billion, up 9.3%. Adjusted EBITDA: Fourth-quarter adjusted EBITDA was $126.9 million, up 15.2%; full-year adjusted EBITDA was $521.7 million, up 13.5%. Adjusted EBITDA Margin: Fourth-quarter margin expanded 120 basis points to 25.3%; full-year margin expanded 100 basis points to 26.7%. Adjusted Net Income: Fourth-quarter adjusted net income increased 16.6% to $72.8 million; full-year adjusted net income increased 15.3% to $294.7 million. Adjusted Earnings Per Share: Fourth-quarter adjusted EPS was $2.09, up 25.9%; full-year adjusted EPS was $8.25, up 23.7%. Operating Cash Flow: Full-year operating cash flow was $471 million, up 41%. Free Cash Flow: Full-year free cash flow was $393 million, up 39%. Chamberlain Revenue: Fourth-quarter revenue increased 3.2% to $190.2 million; adjusted EBITDA increased 3.8% to $46.8 million. Chamberlain Enrollment: Total enrollment grew 1.6%, marking the second consecutive quarter of positive growth. Walden Revenue: Fourth-quarter revenue increased 15.7% to $210.8 million; adjusted EBITDA increased 32.3% to $69.7 million. Walden Enrollment: Total enrollment was up 14% to nearly 55,000 students. MedVet Revenue: Fourth-quarter revenue increased 10.7% to $100.3 million; adjusted EBITDA increased 12.3% to $22.5 million. MedVet Enrollment: Total enrollment was up 7.3% to over 5,100 students. Interest Expense: Full-year interest expense declined to $45.4 million from $52.3 million. Share Repurchases: Returned $238 million to shareholders through share repurchases at an average cost of $98.35. Fiscal 2027 Guidance: Revenue expected in the range of $2.050 billion to $2.090 billion; adjusted EPS expected in the range of $8.90 to $9.15. Warning! GuruFocus has detected 7 Warning Sign with ATLC. Is CVSA fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Covista Inc (NYSE:CVSA) exceeded its fiscal 2026 guidance, with revenue growth of 9.3% to $1.95 billion and adjusted EPS growth of 23.7% to $8.25, both above the high end of raised ranges. The company achieved 12 consecutive quarters of total enrollment growth, with record enrollments at Walden and Chamberlain, reaching 100,000 enrolled students, up from 76,000. Adjusted EBITDA margin expanded by 100 basis points to 26.7% for the full year, reflecting operational leverage and efficiencies across the platform. Free cash flow increased 39% to $393 million, enabling the return of $238 million to shareholders through share repurchases, reducing shares outstanding by 20%. New strategic partnerships, such as with Advocate Health, and campus expansions are expected to drive future growth, with six campuses in active development and three fully approved. The company is investing in AI credentials with Google Cloud, with over 9,000 learners enrolled, and is testing AI-powered classrooms, positioning itself for future technology shifts. Fiscal 2027 guidance implies a slowdown in revenue growth to 5%-7% and adjusted EPS growth to 8%-11%, compared to the stronger growth rates in fiscal 2026. The company faces stronger comparables for Walden and MedVet in fiscal 2027, which could limit growth momentum. The OB3 loan changes caused a pull-forward of enrollments in the fourth quarter, which may shift demand from future periods, creating uncertainty in enrollment trends. Adjusted EBITDA margin expansion is expected to be modest at zero to 50 basis points in fiscal 2027, due to elevated investments in campus expansion and technology. The effective tax rate is expected to be higher in fiscal 2027, which could pressure net income and EPS growth. The company anticipates a higher capital expenditure run rate in fiscal 2027, which could impact free cash flow generation. Q: Can you provide your take on the impact of the OB3 loan changes, including any pull-forward activity you saw before the July 1 deadline and what you've observed since?A: Steve Beard (Chairman and CEO) stated that the company does not anticipate any headwinds for its programs or students from the OB3 loan changes. He acknowledged some pull-forward activity in the MedVet segment, where students attempted to front-run the legislative changes, but characterized this as a consumer-behavior dynamic rather than a shift in underlying demand. He explained that this has shortened the sales cycle for some students, which is a net positive, and that over the two enrollment cycles combined, total enrollment is expected to trend consistent with the company's forecast. Q: What leading indicators are you seeing for Chamberlain as you head into the September enrollment cycle, and how is the broader portfolio shaping up?A: Steve Beard (Chairman and CEO) expressed strong encouragement about Chamberlain's total enrollment trajectory, noting the company is accelerating beyond where it was at the time of Q3 earnings. He highlighted momentum in pre-licensure BSN programs and recovery and stability in post-licensure and graduate programs. He confirmed that all leading indicators, including search data and increased applications, are trading as favorably as they were at the close of Q3, which bodes well for the fall enrollment cycle. Q: How should we think about the scaling of the new Advocate Health partnership and its potential P&L impact for Chamberlain?A: Steve Beard (Chairman and CEO) described the partnership as a strong endorsement from the third-largest non-profit health system in the country. The program will start modestly, focused primarily in North Carolina, but is expected to expand over time, similar to the SSM partnership, which started narrowly and has seen robust demand leading to expanded enrollment targets. He expressed confidence in delivering for Advocate and scaling the success across their markets. Q: Given the recent change in the definition of professional programs to include nursing, are you feeling better about the prospects for those programs?A: Steve Beard (Chairman and CEO) called the development positive, noting it wasn't factored into their initial market opportunity assessment. He reiterated high confidence in supporting students' financing even under the old definition, but acknowledged the change is a net positive, particularly for the nursing profession, and encouraged by the outcome. Q: What impact is the increased consumer adoption of agentic search having on lead volume, quality, or conversion rates?A: Steve Beard (Chairman and CEO) stated that the dynamic has not had any headwind impact on the funnel, particularly at the top. He noted the company got an early start on content development due to the Covista rebranding and now actively tracks brand representation across major AI platforms and answer engines, including visibility and share of voice. He feels good about their handle on the situation and their ability to drive robust top-of-the-funnel activity. Q: Can you provide additional detail on how much of an acceleration in enrollment growth is anticipated in the fiscal 2027 guidance for Chamberlain, and how are applications trending?A: Steve Beard (Chairman and CEO) declined to guide to enrollment growth by institution, but stated that the issue being remediated at Chamberlain over a year ago has been fully addressed. He expressed confidence in the performance of marketing and enrollment teams, the trajectory of new enrollment in pre-licensure nursing, and stabilization in other areas. He expects to keep attractive sequential gains in total enrollment at Chamberlain over fiscal 2027. Q: What were the key drivers of the strong fourth-quarter and full-year financial results?A: Robert Phelan (CFO) reported fourth-quarter revenue increased 9.7% to $501.4 million, driven by all three segments, led by Walden and MedVet. Full-year revenue was $1.954 billion, up 9.3%, exceeding the high end of raised guidance. Adjusted EBITDA for the full year was $521.7 million, up 13.5%, with margins expanding 100 basis points to 26.7%. Adjusted EPS was $8.25, up 23.7%, benefiting from lower interest expense and a reduced share count. Q: What are the key assumptions embedded in the fiscal 2027 guidance?A: Robert Phelan (CFO) provided guidance for fiscal 2027 revenue of $2.050 billion to $2.090 billion (5% to 7% growth) and adjusted EPS of $8.90 to $9.15 (8% to 11% growth). He noted expectations for a positive step-change in Chamberlain's total enrollment, with Walden and MedVet facing stronger comparables. He also highlighted a Walden academic calendar shift impacting quarterly comparisons, with no net impact for the full year, and anticipated adjusted EBITDA margin expansion of zero to 50 basis points. Q: How did the company perform in terms of cash flow and capital returns during fiscal 2026?A: Robert Phelan (CFO) reported full-year operating cash flow of $471 million, up 41%, and free cash flow of $393 million, up 39%. Net leverage improved to 0.5 times from 0.8 times. The company returned $238 million to shareholders through share repurchases at an average cost of $98.35, reducing shares outstanding by 20% over the course of the Growth with Purpose strategy, with $662 million remaining under the repurchase program. Q: What is the outlook for capital expenditures and investments in fiscal 2027?A: Robert Phelan (CFO) stated that capital expenditure run rate is anticipated to be slightly higher than the annualized fourth-quarter fiscal 2026 spend as the company brings new capacity to market. He confirmed continued investment in new technology as one of the pillars of the Purpose at Scale strategy, and noted the effective tax rate is expected to be higher in fiscal 2027 than in fiscal 2026. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Total Q4 enrollment up 8.4% and revenue up 9.7% YoY Chamberlain accelerates total enrollment growth to 1.6% Revenue up 9.3% YoY for fiscal year 2026 Fiscal year 2026 diluted earnings per share $7.04; Adjusted EPS $8.25, growth of 23.7% YoY Fourth quarter highlights GAAP diluted earnings per share $2.06; adjusted EPS $2.09, up 25.9% year-over-year Total student enrollment 99,472, up 8.4% year-over-year, achieved 12th straight quarter of growth Revenue $501.4 million, up 9.7% year-over-year Chamberlain University accelerated total enrollment growth, and achieved 16th straight quarter of pre-licensure BSN total enrollment growth Walden University achieved 12th straight quarter of total enrollment growth, up 14.0% year-over-year, highest total enrollment in university history Medical and Veterinary delivered total enrollment growth of 7.3% year-over-year GAAP net income $71.7 million; adjusted EBITDA $126.9 million, up 15.2% year-over-year Fiscal year highlights Revenue $1,954.1 million, up 9.3% year-over-year Chamberlain University resumed total enrollment growth in second half, and announced two major employer collaborations with leading health systems to address critical healthcare workforce needs Walden University total enrollment up double digits every quarter, delivered the highest total enrollment in university history Medical and Veterinary enrolled approximately 5,250 students on average, up 4.5% year-over-year GAAP net income $251.6 million; adjusted EBITDA $521.7 million, up 13.5% year-over-year Fiscal year capital allocation Repurchased $238 million of shares and repaid $50 million of outstanding Term Loan B debt Successfully refinanced outstanding debt and increased revolving credit capacity, with extended maturities and attractive rates Net leverage of 0.5x as of June 30, 2026 Fiscal year 2027 guidance Revenue in the range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year Adjusted earnings per share in the range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year CHICAGO, August 06, 2026--(BUSINESS WIRE)--Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported fourth quarter and fiscal year 2026 results (ended June 30, 2026). The Company completed its three-year Growth with Purpose strategy and now embarks on its Purpose at Scale strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale. "We completed Growth with Purpose in a position of strength, exceeding both our fiscal 2026 and long-term financial targets. The strategy produced exactly what it was designed to deliver: compounding returns built on sustained investment, deliberate positioning, and a relentless focus on student outcomes. But the results go beyond the financial. They reflect a deeper transformation and vision to be the destination where healthcare ambitions are made possible, graduating professionals who don't just fill jobs, but strengthen the communities where they serve," said Steve Beard, Chairman and Chief Executive Officer, Covista. "We enter our next chapter, Purpose at Scale, powered by an operating model that converts durable healthcare demand into sustainable, profitable growth. Applying that discipline to a larger opportunity is how we create value for our stakeholders and help close the healthcare workforce shortage the country urgently needs solved." Financial Highlights Selected financial data for the three months ended June 30, 2026: Revenue of $501.4 million increased 9.7% compared with the prior year Operating income of $95.4 million, compared with $76.9 million in the prior year; adjusted operating income of $100.9 million, compared with $87.5 million in the prior year Net income of $71.7 million, compared with $54.2 million in the prior year; adjusted net income of $72.8 million, compared with $62.4 million in the prior year Diluted earnings per share of $2.06, compared with $1.44 in the prior year; adjusted earnings per share of $2.09, compared with $1.66 in the prior year Adjusted EBITDA of $126.9 million, compared with $110.2 million in the prior year; adjusted EBITDA margin of 25.3%, compared with 24.1% in the prior year Selected financial data for the fiscal year ended June 30, 2026: Revenue of $1,954.1 million increased 9.3% compared with the prior year Operating income of $383.4 million, compared with $341.5 million in the prior year; adjusted operating income of $419.5 million, compared with $370.2 million in the prior year Net income of $251.6 million, compared with $237.1 million in the prior year; adjusted net income of $294.7 million, compared with $255.6 million in the prior year Diluted earnings per share of $7.04, compared with $6.18 in the prior year; adjusted earnings per share of $8.25, compared with $6.67 in the prior year Adjusted EBITDA of $521.7 million, compared with $459.7 million in the prior year; adjusted EBITDA margin of 26.7%, compared with 25.7% in the prior year Business Highlights Covista and Advocate Health, the third-largest nonprofit integrated health system in the United States, launched a strategic nursing collaboration that creates a clear, financially supported pathway into the nursing profession. Delivered through Chamberlain University, the new collaboration expands access to nursing education and builds a direct pipeline of practice-ready nurses across the communities Advocate Health serves. Chamberlain University continues to make progress with its campus expansion strategy, announcing it will open two new campuses, in Cincinnati and Salt Lake City, which are expected to start classes during the first half of fiscal year 2027. Walden University continues to expand student program offerings; programs launched heading into the 2026 academic year have enrolled more than 1,700 students. Subsequent to the quarter, Walden began enrolling students in four new programs and submitted two additional behavioral health programs for regulatory approval. Covista’s Medical and Veterinary schools (American University of the Caribbean School of Medicine, Ross University School of Medicine and Ross University School of Veterinary Medicine) graduated more than 1,100 students in fiscal year 2026. Medical students from 46 states and 28 countries and veterinary students from 42 states and 8 countries were amongst the graduating class.1 In partnership with Google Cloud, Covista added nine new AI professional certificates during the fourth quarter—including AI applications in veterinary medicine, mental health, and public health, amongst others. In total, Covista has made 12 credentials available to active students, alumni and healthcare professionals, enrolling more than 9,000 learners to date, underscoring how urgently the health professions are seeking AI fluency. Covista has been recognized with multiple national awards honoring the company's workplace culture, employee experience, and commitment to corporate responsibility, including the Forbes list of America’s Best Employers for New Grads 2026 and the 2026-2027 Best Company to Work For - Midwest by U.S. News & World Report. Segment Highlights Chamberlain Total student enrollment increased 1.6% compared with the prior year, driven by growth in pre-licensure nursing. Walden Total student enrollment increased 14.0% compared with the prior year, driven by growth in healthcare and non-healthcare programs. Medical and Veterinary Total student enrollment increased 7.3% compared with the prior year, driven by growth in both medical and veterinary. Fiscal Year 2027 Outlook Covista initiates guidance for fiscal year 2027, including: Revenue in the range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year. Adjusted earnings per share in the range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year. "We are entering the first year of Purpose at Scale with enhanced momentum, reflecting our strong finish to fiscal year 2026. The overall financial performance trajectory allows us to provide compelling guidance for fiscal year 2027. Taken together, we are tracking ahead of where we expected we would be with regard to our long-term targets," said Beard. Conference Call and Webcast Information Covista will hold a conference call to discuss its fourth quarter and fiscal year 2026 results today at 4:00 p.m. CT (5:00 p.m. ET). The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating "Covista earnings call" or by using conference ID:13761006. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com. Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13761006, or visit the Covista investor relations website. About Covista Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit Covista.com and follow us on LinkedIn, Instagram and YouTube. Cautionary Disclosure Regarding Forward-Looking Statements Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "future," "believe," "project," "expect," "anticipate," "estimate," "plan," "intend," "may," "will," "would," "could," "can," "continue," "preliminary," "potential," "range," and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. "Risk Factors," of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP. Covista Inc.Non-GAAP Financial Measures and Reconciliations We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables: Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations. Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, tax benefit due to change in unrecognized tax benefits, and loss (income) from discontinued operations. Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income. Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures. Net debt – Defined as total long-term debt principal less cash and cash equivalents. Net leverage – Defined as net debt divided by adjusted EBITDA. A description of special items in our non-GAAP financial measures described above are as follows: Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Covista’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense. Amortization of acquired intangible assets. Amortization of cloud computing implementation assets. Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs. Loss on debt extinguishment related to amendments and repayments of our Senior Secured Notes due 2028, Term Loan B, and Revolver. Reserves related to significant litigation. Asset impairments related to adjusting certain operating lease assets and property and equipment as a result of adjusting carrying values to fair values. Loss on assets held for sale related to adjusting those assets to estimated fair value less costs to sell. Debt modification costs related to refinancing our Term Loan B. Tax benefit due to change in unrecognized tax benefits. Loss (income) from discontinued operations includes activity from ongoing litigation costs and settlements related to divestitures and the earn-outs we received. View source version on businesswire.com: https://www.businesswire.com/news/home/20260806254421/en/ Contacts Investor Contact: Jeremy [email protected] +1 312-906-6600 Media Contact: Maureen [email protected]

Covista (CVSA) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.9 per share. This compares to earnings of $1.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +10.00%. A quarter ago, it was expected that this for-profit education company would post earnings of $1.73 per share when it actually produced earnings of $1.98, delivering a surprise of +14.45%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Covista, which belongs to the Zacks Schools industry, posted revenues of $501.38 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.38%. This compares to year-ago revenues of $457.11 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Covista shares have added about 24.6% since the beginning of the year versus the S&P 500's gain of 12.8%. While Covista has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Covista was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.00 on $494.87 million in revenues for the coming quarter and $8.85 on $2.07 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Schools is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. KinderCare Learning Companies, Inc. (KLC), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -54.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. KinderCare Learning Companies, Inc.'s revenues are expected to be $696.93 million, down 0.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Covista Inc. (CVSA) : Free Stock Analysis Report KinderCare Learning Companies, Inc. (KLC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Covista Inc. CVSA is scheduled to report its fourth-quarter fiscal 2026 results on Aug. 6, after market close.In the last reported quarter, the company’s adjusted earnings per share (EPS) and revenues topped the Zacks Consensus Estimate by 14.5% and 1.9%, respectively. Also, year over year, both metrics grew 3.1% and 4.5%, respectively.CVSA’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 11.7%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS has remained unchanged at $1.90 over the past 60 days. However, the estimated figure indicates 14.5% growth from the year-ago quarter’s earnings of $1.66 per share.The consensus estimate for revenues is pegged at $485 million, indicating an improvement of 6.1% from the prior-year quarter. Covista Inc. price-eps-surprise | Covista Inc. Quote RevenuesDuring the fiscal fourth quarter, the top-line performance of Covista is expected to have increased year over year on the back of strong student enrollment due to elevated demand for healthcare professionals. Moreover, the education provider’s efforts toward AI infusion in its offerings, marketing investments, revamped education model and accretive collaborations are likely to have additionally bolstered the quarterly growth.The advantageous positioning of CVSA between the favorable demand trends for healthcare professionals and its in-house efforts of offering perfectly aligned educational services is expected to have boosted enrollment. This, in turn, is likely to have led to favorable contributions from CVSA’s three reportable segments - Chamberlain (contributed 40.5% to third quarter fiscal 2026 revenues), Walden University (contributed 38.3% to third quarter fiscal 2026 revenues) and Medical and Veterinary (contributed 21.3% to third quarter fiscal 2026 revenues).For the fiscal fourth quarter, the Zacks Consensus Estimate for revenues from Chamberlain, Walden University and Medical and Veterinary segments is pegged at $188 million, $202 million and $95 million, reflecting year-over-year growth of 2.2%, 11% and 4.4%, respectively.The quarter’s enrollment across Chamberlain, Walden University and Medical and Veterinary segments is expected to be 39,891, 52,424 and 4,819 students, indicating year-over-year growth from 38,891, 48,116 and 4,773 students, respectively. Our model also expects CVSA’s fiscal fourth-quarter total enrollment to be up year over year 5.8% to 97,135 students.EarningsCovista is expected to report year-over-year bottom-line growth in the fiscal fourth quarter, because of its exemplary cost-saving measures through workforce reductions, centralized operations and tighter control over discretionary spending. The company’s efforts to manage its cost base through tighter controls on discretionary spending and ongoing operational discipline, while still funding growth initiatives, are an encouraging aspect.The Zacks Consensus Estimate for operating income of the Walden University and Medical and Veterinary segments is pegged at $51 million and $18.51 million, reflecting respective growth from $44 million and $14.9 million, reported a year ago. However, the operating income of the Chamberlain segment is expected to decline in the fiscal fourth quarter to $34.6 million from $35.7 million reported a year ago, somewhat offsetting further bottom-line growth.Nonetheless, Covista’s search for opportunities to invest in growth, create durable operational leverage, ensure sustainable student enrollment growth and enhance business persistence is expected to expand its margins in the upcoming period. Our proven model does not predict an earnings beat for Covista this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, it is not the case this time around.CVSA’s Earnings ESP: The company has an Earnings ESP of 0.00%. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.CVSA’s Zacks Rank: The stock currently has a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here. Here are some companies in the Zacks Consumer Discretionary sector, which according to our model, have the right combination of elements to post an earnings beat.Six Flags Entertainment Corporation FUN has an Earnings ESP of +6.90% and a Zacks Rank of 1 at present. Six Flags’ earnings beat estimates in two of the last four quarters and missed on the other two occasions, the average negative surprise being 48.9%. The company’s earnings for the second quarter of 2026 are expected to improve 11.5% year over year.Corsair Gaming, Inc. CRSR currently has an Earnings ESP of +9.09% and a Zacks Rank of 2.Corsair’s earnings beat estimates in two of the last four quarters, missed on one occasion and met on the remaining occasion, the average surprise being 22.6%. The company’s earnings for the second quarter of 2026 are expected to surge 600% year over year.Marriott Vacations Worldwide Corporation VAC has an Earnings ESP of +5.26% and a Zacks Rank of 2.Marriott Vacations’ earnings beat estimates in three of the last four quarters and missed on the remaining occasion, the average surprise being 0.7%. The company’s earnings for the second quarter of 2026 are expected to inch up 1% year over year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Covista Inc. (CVSA) : Free Stock Analysis Report Marriott Vacations Worldwide Corporation (VAC) : Free Stock Analysis Report Six Flags Entertainment Corporation (FUN) : Free Stock Analysis Report Corsair Gaming, Inc. (CRSR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Laureate Education (LAUR) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.17%. A quarter ago, it was expected that this for-profit higher education purveyor would post a loss of $0.17 per share when it actually produced a loss of $0.17, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Laureate Education, which belongs to the Zacks Schools industry, posted revenues of $615.9 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.29%. This compares to year-ago revenues of $524.2 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Laureate Education shares have added about 14.1% since the beginning of the year versus the S&P 500's gain of 6.9%. While Laureate Education has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Laureate Education was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $476.3 million in revenues for the coming quarter and $2.09 on $1.92 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Schools is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Covista (CVSA), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 6. This for-profit education company is expected to post quarterly earnings of $1.90 per share in its upcoming report, which represents a year-over-year change of +14.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Covista's revenues are expected to be $485.01 million, up 6.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Laureate Education (LAUR) : Free Stock Analysis Report Covista Inc. (CVSA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

In May 2026, Covista Inc. reported third-quarter sales of US$487.03 million and net income of US$41.64 million, while also updating nine‑month results that showed higher sales but slightly lower net income compared to a year earlier. On the same day, Covista raised its full‑year 2026 revenue guidance and confirmed it had repurchased 870,290 shares for US$88.19 million, highlighting management’s confidence and ongoing use of buybacks to reduce the share count. We’ll now explore how Covista’s higher full‑year revenue guidance reshapes the existing investment narrative built around healthcare education demand. Uncover the next big thing with 27 elite penny stocks that balance risk and reward. To own Covista, you need to believe that persistent health care workforce needs will keep demand steady for its nursing, medical and allied health programs. The key near term catalyst remains revenue momentum from those programs, and the raised 2026 revenue guidance supports that story. The biggest risk is still pressure on enrollment and affordability if regulatory or funding conditions for students tighten, and this latest update does not materially change that risk profile. The most relevant announcement here is Covista’s higher 2026 revenue guidance to US$1,930 million to US$1,945 million, pointing to about 8% to 9% year over year growth. That sits alongside an active buyback program and follows the Q3 update showing higher sales but softer net income. Together, they keep the focus on whether revenue growth can translate into sustained earnings expansion, especially as Covista invests in capacity and digital learning across Walden, Chamberlain and its Med/Vet programs. Yet even with raised guidance, investors should be aware that any shift in student lending rules could... Read the full narrative on Covista (it's free!) Covista's narrative projects $2.3 billion revenue and $348.8 million earnings by 2029. This requires 7.0% yearly revenue growth and a $94.8 million earnings increase from $254.0 million today. Uncover how Covista's forecasts yield a $153.25 fair value, a 22% upside to its current price. Some of the most optimistic analysts were already assuming revenue would reach about US$2.3 billion and earnings US$380.6 million, which is far more upbeat than the consensus view and leans heavily on strong cash flow and large buybacks, while the latest earnings and guidance suggest both this optimistic scenario and the risk of weaker enrollment at Chamberlain might need a fresh look. Explore 3 other fair value estimates on Covista - why the stock might be worth just $153.25! Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your Covista research is our analysis highlighting 4 key rewards that could impact your investment decision. Our free Covista research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Covista's overall financial health at a glance. Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters: AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Find 54 companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CVSA. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Covista delivered a positive first quarter, surpassing Wall Street’s expectations for both revenue and non-GAAP earnings. Management highlighted that robust enrollment growth across all segments, particularly at Chamberlain and Walden universities, was the primary driver of performance. CEO Stephen Beard cited a return to positive total enrollment at Chamberlain, noting, “The operating changes that we committed to are, in fact, working.” Operational improvements in marketing and application processes also contributed to these results, reinforcing the company’s ability to execute its strategy. Is now the time to buy CVSA? Find out in our full research report (it’s free). Revenue: $487 million vs analyst estimates of $474 million (4.5% year-on-year growth, 2.7% beat) Adjusted EPS: $1.98 vs analyst estimates of $1.72 (14.9% beat) Adjusted EBITDA: $127.9 million vs analyst estimates of $117.7 million (26.3% margin, 8.6% beat) The company slightly lifted its revenue guidance for the full year to $1.94 billion at the midpoint from $1.92 billion Management raised its full-year Adjusted EPS guidance to $8.05 at the midpoint, a 1.9% increase Operating Margin: 18.8%, in line with the same quarter last year Market Capitalization: $4.38 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ryan Griffin (BMO Capital Markets) asked for an update on employer partnerships like SSM. CEO Stephen Beard replied that SSM continues to thrive and that new partnership discussions are underway, though no specifics were disclosed. Ryan Griffin (BMO Capital Markets) questioned whether fourth quarter investments were shifted from Q3. CFO Robert Phelan clarified that incremental investments were planned for Q4, not timing shifts from the previous quarter. Jasper Bibb (Truist Securities) inquired about the drivers behind Chamberlain’s enrollment reversal and RN to BSN demand. Beard explained that marketing and process improvements drove the turnaround, with renewed momentum in post-licensure programs. Jasper Bibb (Truist Securities) sought clarification on application conversions at Chamberlain. Beard confirmed that conversion rates have normalized to historical levels due to personnel and process enhancements. Jack Slevin (Jefferies) asked about CapEx trends as new campuses roll out. Phelan responded that capital expenditures will ramp up in the fourth quarter and serve as a proxy for future run rates as expansion continues. In upcoming quarters, our team will watch closely for (1) continued enrollment momentum at Chamberlain and Walden, especially as new campuses come online; (2) adoption rates and student outcomes from AI-powered learning initiatives and credential programs; and (3) progress on employer partnerships that could enhance student placement and institutional relevance. Execution on campus buildouts and integration of new leadership will also be critical markers. Covista currently trades at $128.79, up from $117 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free for active Edge members). ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively. Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.